Cargando…
Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation
Introduction: Four-dimensional (4-D) flow cardiac magnetic resonance imaging can be used to elegantly describe the hemodynamic efficiency of left ventricular (LV) flow throughout the cardiac cycle. Patients with nonvalvular paroxysmal atrial fibrillation (PAF) may have occult LV disease. Flow distri...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657405/ https://www.ncbi.nlm.nih.gov/pubmed/34900953 http://dx.doi.org/10.3389/fbioe.2021.725121 |
_version_ | 1784612495522004992 |
---|---|
author | Kim, Hansuk Sheitt, Hana Wilton, Stephen B. White, James A. Garcia, Julio |
author_facet | Kim, Hansuk Sheitt, Hana Wilton, Stephen B. White, James A. Garcia, Julio |
author_sort | Kim, Hansuk |
collection | PubMed |
description | Introduction: Four-dimensional (4-D) flow cardiac magnetic resonance imaging can be used to elegantly describe the hemodynamic efficiency of left ventricular (LV) flow throughout the cardiac cycle. Patients with nonvalvular paroxysmal atrial fibrillation (PAF) may have occult LV disease. Flow distribution analysis, based on 4-D flow, may unmask the presence of LV disease by assessing flow components: direct flow, retained flow, delayed ejection, and residual volume. This study aimed to identify LV hemodynamic inefficiencies in patients with PAF and normal systolic function. We hypothesized that the fraction of direct flow to the total end-diastolic volume would be reduced in patients with PAF compared with controls. Methods: We used 4-D LV flow component analysis to compare hemodynamics in 30 healthy controls and 50 PAF patients in sinus rhythm. Results: PAF subjects and healthy controls had similar LV mass, volume, and ejection fraction. Direct flow was lower in the PAF group than in the controls (44.5 ± 11.2% vs. 50.0 ± 12.2%, p = 0.042) while delayed ejection was higher in the PAF group (21.6 ± 5.6% vs. 18.6 ± 5.7%, p = 0.022). Conclusion: PAF patients demonstrated a relative reduction in direct flow and elevation in delayed ejection. |
format | Online Article Text |
id | pubmed-8657405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86574052021-12-10 Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation Kim, Hansuk Sheitt, Hana Wilton, Stephen B. White, James A. Garcia, Julio Front Bioeng Biotechnol Bioengineering and Biotechnology Introduction: Four-dimensional (4-D) flow cardiac magnetic resonance imaging can be used to elegantly describe the hemodynamic efficiency of left ventricular (LV) flow throughout the cardiac cycle. Patients with nonvalvular paroxysmal atrial fibrillation (PAF) may have occult LV disease. Flow distribution analysis, based on 4-D flow, may unmask the presence of LV disease by assessing flow components: direct flow, retained flow, delayed ejection, and residual volume. This study aimed to identify LV hemodynamic inefficiencies in patients with PAF and normal systolic function. We hypothesized that the fraction of direct flow to the total end-diastolic volume would be reduced in patients with PAF compared with controls. Methods: We used 4-D LV flow component analysis to compare hemodynamics in 30 healthy controls and 50 PAF patients in sinus rhythm. Results: PAF subjects and healthy controls had similar LV mass, volume, and ejection fraction. Direct flow was lower in the PAF group than in the controls (44.5 ± 11.2% vs. 50.0 ± 12.2%, p = 0.042) while delayed ejection was higher in the PAF group (21.6 ± 5.6% vs. 18.6 ± 5.7%, p = 0.022). Conclusion: PAF patients demonstrated a relative reduction in direct flow and elevation in delayed ejection. Frontiers Media S.A. 2021-11-25 /pmc/articles/PMC8657405/ /pubmed/34900953 http://dx.doi.org/10.3389/fbioe.2021.725121 Text en Copyright © 2021 Kim, Sheitt, Wilton, White and Garcia. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Kim, Hansuk Sheitt, Hana Wilton, Stephen B. White, James A. Garcia, Julio Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
title | Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
title_full | Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
title_fullStr | Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
title_full_unstemmed | Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
title_short | Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
title_sort | left ventricular flow distribution as a novel flow biomarker in atrial fibrillation |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657405/ https://www.ncbi.nlm.nih.gov/pubmed/34900953 http://dx.doi.org/10.3389/fbioe.2021.725121 |
work_keys_str_mv | AT kimhansuk leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT sheitthana leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT wiltonstephenb leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT whitejamesa leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT garciajulio leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation |